The lab of Yongchao C. Ma, PhD, at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago uncovered a novel mechanism that leads to motor neuron ...

Spinal Muscular Atrophy (SMA) is a rare genetic disorder characterized by the progressive weakening of muscles due to the degeneration of motor neurons in the spinal cord. This condition is caused ...

Spinal muscular atrophy (SMA) is a genetic condition that leads to a progressive loss of nerve cells called “lower motor neurons” in the spinal cord.

Spinal muscular atrophy is a disease that most often strikes babies and young children, ... It's caused by changes, or mutations, in a gene called the survival motor neuron gene 1 (SMN1).

Adult-onset spinal muscular atrophy occurs over the age of 18, and commonly in a person's 30s or 40s. ... SMN2 survival of motor neuron 2, centromeric [ Homo sapiens (human) ].

For spinal muscular atrophy (SMA), a progressive motor neuron disease, developing a gene therapy that edits the DNA may be the key to correcting an evolutionary genetic mistake. In patients with SMA, ...

For the first time ever, doctors have treated a rare genetic disease known as spinal muscular atrophy (SMA) in the womb – and ...

Source Reference: Crawford TO, et al "Safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3" Neurology 2024; DOI: 10.1212/WNL.000000000020915.

Spinal muscular atrophy is a disease that is usually seen in babies and children. It makes their muscles weak and hard to move. ... Changes or defects in the SMN (survival motor neuron) ...

Treatment with nusinersen was linked to increased motor function and reduction of the neurodegenerative biomarker neurofilament light chain in children with spinal muscular atrophy, according to ...

Covina, Feb. 15, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Spinal Muscular Atrophy Market size was valued at about USD 1.4 Billion in 2024 and expected to grow at ...

The U.S. Food and Drug Administration (FDA) granted fast track designation to Biohaven (NYSE:BHVN) medicine taldefgrobep alfa to treat spinal muscular atrophy (SMA). SMA is an inherited motor ...